Company Analysis

IN8bio, Inc. (INAB)

Nasdaq: INAB · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2018
Grade5.0
◀ Past 3.4● Present 4.6▶ Future 6.3
6 est.

Who runs IN8bio, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Ho William Tai-Wei
CEO. First filing Jul 2021, latest May 12, 2026, 2 filings in all.
Officers reporting now
4
of 10 people with a filing in the last fifteen months
Directors reporting now
6
28 people on the record since 2021
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Ho William Tai-WeiCEOJul 2021May 12, 2026none
Rochlin KatePresident and COODec 2021May 12, 2026none
Mccall PatrickCHIEF FINANCIAL OFFICERJul 2021May 12, 2026none
Lamb LawrenceEVP and CSOJul 2021May 12, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Fairbairn EmilydirectorJul 2021May 29, 2026none
Brandt Peter C.directorJul 2021May 12, 2026none
Epperly CorinnedirectorDec 2023May 12, 2026none
Graff Jeremy R.directorMay 2023May 12, 2026none
Greenwood LubadirectorJul 2021May 12, 2026none
Roemer Alan S.directorJul 2021Dec 23, 2025none
Earlier names on the record23, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton INAB · research, not advice